What is the recommended evaluation and management for a patient with a 5 × 4 cm retroperitoneal fat‑containing mass on CT and an estimated glomerular filtration rate of 24 mL/min/1.73 m²?

Retroperitoneal Fat-Containing Mass with Severe CKD

Given the presence of macroscopic fat in this 5 × 4 cm retroperitoneal mass, this is almost certainly a benign angiomyolipoma (AML), and with a GFR of 24 mL/min/1.73 m² (stage 4 CKD), you should proceed with MRI abdomen without and with IV contrast using a group II macrocyclic gadolinium agent to definitively characterize this lesion while minimizing nephrotoxicity risk.

Key Diagnostic Considerations

Fat-Containing Mass Characteristics

The presence of macroscopic fat in a retroperitoneal mass indicates a benign angiomyolipoma with virtual certainty 1. However, the critical question is whether this represents:

• Classic AML with readily apparent macroscopic fat (benign, no intervention needed)
• Lipid-poor AML with minimal fat that could mimic renal cell carcinoma
• Well-differentiated liposarcoma (rare but possible in retroperitoneum)

The Severe Renal Impairment Challenge

With a GFR of 24 mL/min/1.73 m², this patient has stage 4 CKD, which creates significant imaging constraints:

• Iodinated CT contrast is relatively contraindicated due to high risk of contrast-induced nephropathy 1
• Group I gadolinium agents carry NSF risk and should be avoided 2
• Group II/III macrocyclic gadolinium agents are safe - the benefit of diagnostic imaging outweighs minimal NSF risk in this population 2

Recommended Diagnostic Algorithm

Step 1: Review Existing CT Imaging Carefully

Examine the current CT chest for:

• Homogeneous attenuation values: If the mass measures <20 HU or >70 HU on noncontrast imaging, it can be characterized as benign 1
• Amount and distribution of fat: Abundant macroscopic fat throughout = classic AML (benign)
• Calcifications or soft tissue components: Suggest possible malignancy
• Relationship to kidney: Perirenal vs. truly retroperitoneal location matters

Step 2: Obtain MRI Abdomen Without and With IV Contrast

This is the optimal next step 1. MRI provides superior characterization compared to noncontrast CT and avoids nephrotoxic iodinated contrast.

Technical specifications:

• Use group II macrocyclic gadolinium-based contrast (gadobutrol, gadoterate meglumine, or gadoteridol) 2
• Include T1-weighted, T2-weighted, and fat-suppressed sequences
• Obtain pre-contrast and post-contrast imaging to assess enhancement patterns
• The 15% enhancement threshold distinguishes cysts from solid tumors 1

Why MRI is superior here:

• Higher specificity than CT for characterizing renal/retroperitoneal masses (68.1% vs 27.7%) 1
• Can detect small amounts of fat better than contrast-enhanced CT 1
• T2-weighted imaging provides additional tissue characterization
• Safe in stage 4 CKD when using appropriate gadolinium agents 2

Step 3: Consider Percutaneous Biopsy If Imaging Remains Indeterminate

Biopsy should be strongly considered if 1:

• Imaging features suggest but don't confirm benign fat-poor AML
• There are atypical features raising concern for liposarcoma
• The mass shows heterogeneous enhancement or soft tissue components

Biopsy advantages in this context:

• Diagnostic in 80.6% of cases 1
• Low complication rate (0.9% significant complications) 1
• Can prevent unnecessary surgery, especially important given this patient's renal function
• One-third of biopsied "indeterminate" masses prove benign 1

Critical caveat: A nondiagnostic biopsy cannot be considered evidence of benignity - repeat biopsy may be needed 1

Management Based on Diagnosis

If Classic AML (Most Likely)

• No intervention needed for asymptomatic lesions <4 cm
• This 5 cm mass warrants surveillance imaging due to bleeding risk
• Consider prophylactic embolization or surgery if symptomatic or growing

If Lipid-Poor AML

• Biopsy confirmation recommended 1
• Active surveillance is appropriate for confirmed benign histology
• Preserving renal function is paramount given GFR of 24

If Liposarcoma (Unlikely but Possible)

• Requires complete surgical resection with negative margins 3
• Kidney-sparing approach should be prioritized given stage 4 CKD 3
• The patient's young age (implied by need for long-term renal function preservation) favors nephron-sparing surgery when feasible

Critical Pitfalls to Avoid

1. Do NOT use iodinated CT contrast - the risk of further renal injury outweighs diagnostic benefit when MRI is available 1

2. Do NOT use group I linear gadolinium agents (gadodiamide, gadopentetate dimeglumine, gadoversetamide) - these carry NSF risk in stage 4 CKD 2

3. Do NOT assume fat = benign without proper characterization - well-differentiated liposarcomas can occur in retroperitoneum 3

4. Do NOT dismiss the mass as "just a lipoma" - a 5 cm retroperitoneal fat-containing mass requires definitive diagnosis

5. Do NOT proceed directly to nephrectomy without tissue diagnosis - preserving renal function is critical with GFR of 24, and one-third of biopsied masses prove benign 1